All In Biotech

Drug Trial Radar · NCT04105543

CLR 131 Combined With Radiation for Head and Neck Cancer

Therapeutic Combination of CLR 131 With External Beam Radiation in Head and Neck Cancer

Last checked: Nov 19, 2026Latest source record: Sep 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Dec 20, 2019

Primary completion

Sep 19, 2022

Study completion Feb 1, 2024

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences, Inc.
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 study of the use of an investigational drug that selectively delivers radiation to malignant tumor cells, CLR 131, in combination with external beam radiation therapy (EBRT) in subjects with locoregionally recurrent head and neck cancer. The trial will enroll up to 12 participants who are amenable to retreatment with radiation therapy. Participants who also have distant metastatic disease may be enrolled on this clinical trial, but they must have evaluable disease that will be clinically treated with radiation therapy, as per standard of care. All participants will receive a dosimetry test dose of CLR 131 to establish drug uptake by the tumor and enable Monte Carlo dose estimation based on CLR 131 SPECT/CT imaging evaluation. Participants showing uptake will receive a cumulative tumor dose of 60-70 Gy using personalized dose calculation (via Monte Carlo methods) of CLR 131 combined with external beam radiation.

Conditions

  • Head and Neck Cancer

Interventions

  • CLR 131Drug

    CLR 131 is a radiopharmaceutical dosed intravenously over a period of approximately 30 minutes, dose will be based on total body surface area calculated from actual body weight and height

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Related Adverse EventsTime frame: up to 18 weeks
  2. Summary of Adverse Events Possibly Related to TreatmentTime frame: up to 18 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • UW Cancer Center Johnson Creek

    Johnson Creek, Wisconsin

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.